Pfizer To Put Big Marketing Muscle Behind Migraine With Biohaven Purchase
Executive Summary
Pfizer’s $11.6bn acquisition of the company brings it full rights to the oral migraine drug Nurtec ODT and nasal spray zevegepant, with aims to build a $6bn migraine franchise.
You may also be interested in...
In Vivo’s Deals Of The Year: Cast Your Vote!
It is time for In Vivo's 15th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
Pfizer's Plan To Establish A $6bn Migraine Franchise
Pfizer's strategy for building a mega-blockbuster brand around Nurtec ODT involves establishing oral CGRPs as first-line treatment.
The Busiest Dealmakers Of 2022
With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.